Metropolis Healthcare reports 25.8% profit rise in first quarter

Metropolis Healthcare Ltd. reported a 25.8% year-on-year increase in consolidated net profit for the June quarter ^[1].

The results signal a shift toward volume-led growth in the Indian diagnostics market, suggesting that demand for specialty testing and wellness packages can offset the decision to keep pricing stable.

The Mumbai-based provider saw its net profit rise to Rs 56.7 crore, up from Rs 45 crore in the same period last year ^[1]. This growth occurred despite the company ruling out price hikes for the current year ^[2].

Company leadership said the performance was due to a combination of increased patient volume and higher realizations from specific service lines. Approximately 10% of the growth was driven by volume ^[2]. The remainder of the growth came from the specialty testing portfolio and the TruHealth wellness programme ^[2].

"Around 9-10% of the company's targeted growth will be volume-led, while the remaining growth is expected to come from improved realisations driven by its TruHealth wellness programme and specialty testing portfolio," C. Surendran, Managing Director of Metropolis Healthcare, said ^[2].

Looking ahead to the remainder of the fiscal year, the company expects a margin improvement of 100-150 basis points ^[3]. This projection comes as the firm focuses on expanding its diagnostic reach while maintaining its current pricing structure to attract a broader customer base.

Industry analysts have noted the healthy volume growth, though some still maintain preferences for competitors like Dr Lal Pathlabs ^[1]. Metropolis continues to leverage its presence in the Mumbai market to scale its operations, a strategy that has so far yielded a significant double-digit profit jump.